Sangeetha M Reddy

List of Publications by Citations

23 papers	3,240 citations	16 h-index	28 g-index
28 ext. papers	4,648 ext. citations	13.9 avg, IF	4.47 L-index

#	Paper	IF	Citations
23	B cells and tertiary lymphoid structures promote immunotherapy response. *Nature*, **2020**, 577, 549-555	50.4	654
22	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. *Cell*, **2018**, 175, 998-1013.e20	56.2	631
21	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. *Cancer Discovery*, **2016**, 6, 827-37	24.4	561
20	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. *Science Translational Medicine*, **2017**, 9,	17.5	409
19	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. *Nature Medicine*, **2018** , 24, 1649-1654	50.5	377
18	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. *Lancet Oncology, The*, **2018**, 19, 181-193	21.7	168
17	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. *Npj Genomic Medicine*, **2017**, 2,	6.2	82
16	Monitoring immune responses in the tumor microenvironment. *Current Opinion in Immunology*, **2016**, 41, 23-31	7.8	76
15	Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. *Cancer Research*, **2017**, 77, 5374-5383	10.1	60
14	Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. *Cancer Immunology Research*, **2019**, 7, 1025-1035	12.5	42
13	Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. *Current Oncology Reports*, **2016**, 18, 42	6.3	36
12	Atezolizumab for the treatment of breast cancer. *Expert Review of Anticancer Therapy*, **2020**, 20, 151-158	3.5	24
11	Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies. *Clinical Colorectal Cancer*, **2016**, 15, 37-46	3.8	23
10	Targeting angiogenesis in metastatic breast cancer. *Oncologist*, **2012**, 17, 1014-26	5.7	19
9	Interaction of molecular alterations with immune response in melanoma. *Cancer*, **2017**, 123, 2130-2142	6.4	18
8	Impact of Statin Use on Outcomes in Triple Negative Breast Cancer. *Journal of Cancer*, **2017**, 8, 2026-2032	4.5	18
7	Effect of Doxorubicin on Myocardial Bicarbonate Production From Pyruvate Dehydrogenase in Women With Breast Cancer. *Circulation Research*, **2020**, 127, 1568-1570	15.7	10

List of Publications

6	Mast Cells: A New Frontier for Cancer Immunotherapy. *Cells*, **2021**, 10,	7.9	10
5	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. *Nature Communications*, **2020**, 11, 1839	17.4	9
4	New horizons in imaging and surgical assessment of breast cancer lymph node metastasis. *Breast Cancer Research and Treatment*, **2021**, 187, 311-322	4.4	3
3	Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers. *Genome Medicine*, **2021**, 13, 70	14.4	2
2	Abstract GS2-10: Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC). *Cancer Research*, **2022**, 82, GS2-10-GS2-10	10.1	0
1	Prognostic and Predictive Markers in Colorectal Cancer. *Current Colorectal Cancer Reports*, **2011**, 7, 267	1	